Apolipoproteins and amyloid fibril formation in atherosclerosis

Protein and Cell

Volumn 2, Issue 2, 2011, Pages 116-127

  Teoh, Chai Lean ^a,b   Griffin, Michael D W ^a,b   Howlett, Geoffrey J ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

amyloid fibril; apolipoproteins; atherosclerosis; misfolding

Indexed keywords

ALPHA CRYSTALLIN; AMYLOID; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C2; APOLIPOPROTEIN E; BETA CRYSTALLIN; CHAPERONE; METHIONINE; PHOSPHOLIPID; SERUM AMYLOID P;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ATHEROGENESIS; ATHEROSCLEROSIS; DISEASE COURSE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR MECHANICS; NONHUMAN; OXIDATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; REVIEW;

EID: 79953215653     PISSN: 1674800X     EISSN: 16748018     Source Type: Journal    
DOI: 10.1007/s13238-011-1013-6     Document Type: Review

References (119)

1. Acharya, P., Segall, M. L., Zaiou, M., Morrow, J., Weisgraber, K. H., Phillips, M. C., Lund-Katz, S., and Snow, J. (2002). Comparison of the stabilities and unfolding pathways of human apolipoprotein E isoforms by differential scanning calorimetry and circular dichroism. Biochim Biophys Acta 1584, 9-19.
2. Alexandrescu, A. T. (2005). Amyloid accomplices and enforcers. Protein Sci 14, 1-12.
3. Anantharamaiah, G. M., Hughes, T. A., Iqbal, M., Gawish, A., Neame, P. J., Medley, M. F., and Segrest, J. P. (1988). Effect of oxidation on the properties of apolipoproteins A-I and A-II. J Lipid Res 29, 309-318.
4. Andersen, C. B., Yagi, H., Manno, M., Martorana, V., Ban, T., Christiansen, G., Otzen, D. E., Goto, Y., and Rischel, C. (2009). Branching in amyloid fibril growth. Biophys J 96, 1529-1536.
5. Andreola, A., Bellotti, V., Giorgetti, S., Mangione, P., Obici, L., Stoppini, M., Torres, J., Monzani, E., Merlini, G., and Sunde, M. (2003). Conformational switching and fibrillogenesis in the amyloidogenic fragment of apolipoprotein a-I. J Biol Chem 278, 2444-2451.
6. Anfinsen, C. B. (1973). Principles that govern the folding of protein chains. Science 181, 223-230.
7. Ban, T., Hamada, D., Hasegawa, K., Naiki, H., and Goto, Y. (2003). Direct observation of amyloid fibril growth monitored by thioflavin T fluorescence. J Biol Chem 278, 16462-16465.
8. Ban, T., Hoshino, M., Takahashi, S., Hamada, D., Hasegawa, K., Naiki, H., and Goto, Y. (2004). Direct observation of Abeta amyloid fibril growth and inhibition. J Mol Biol 344, 757-767.
9. Ban, T., Morigaki, K., Yagi, H., Kawasaki, T., Kobayashi, A., Yuba, S., Naiki, H., and Goto, Y. (2006a). Real-time and single fibril observation of the formation of amyloid beta spherulitic structures. J Biol Chem 281, 33677-33683.
10. Ban, T., Yamaguchi, K., and Goto, Y. (2006b). Direct observation of amyloid fibril growth, propagation, and adaptation. Acc Chem Res 39, 663-670.
11. Benson, M. D., Liepnieks, J. J., Yazaki, M., Yamashita, T., Hamidi Asl, K., Guenther, B., and Kluve-Beckerman, B. (2001). A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene. Genomics 72, 272-277.
12. Binger, K. J., Griffin, M. D., Heinemann, S. H., and Howlett, G. J. (2010). Methionine-oxidized amyloid fibrils are poor substrates for human methionine sulfoxide reductases A and B2. Biochemistry 49, 2981-2983.
13. Binger, K. J., Griffin, M. D., and Howlett, G. J. (2008a). Methionine oxidation inhibits assembly and promotes disassembly of apolipoprotein C-II amyloid fibrils. Biochemistry 47, 10208-10217.
14. Binger, K. J., Pham, C. L., Wilson, L. M., Bailey, M. F., Lawrence, L. J., Schuck, P., and Howlett, G. J. (2008b). Apolipoprotein C-II amyloid fibrils assemble via a reversible pathway that includes fibril breaking and rejoining. J Mol Biol 376, 1116-1129.
15. Booth, D. R., Tan, S. Y., Booth, S. E., Hsuan, J. J., Totty, N. F., Nguyen, O., Hutton, T., Vigushin, D. M., Tennent, G. A., Hutchinson, W. L., et al. (1995). A new apolipoprotein Al variant, Trp50Arg, causes hereditary amyloidosis. QJM 88, 695-702.
16. Booth, D. R., Tan, S. Y., Booth, S. E., Tennent, G. A., Hutchinson, W. L., Hsuan, J. J., Totty, N. F., Truong, O., Soutar, A. K., Hawkins, P. N., et al. (1996). Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene. J Clin Invest 97, 2714-2721.
17. Bosco, D. A., Fowler, D. M., Zhang, Q., Nieva, J., Powers, E. T., Wentworth, P. Jr, Lerner, R. A., and Kelly, J. W. (2006). Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol 2, 249-253.
18. Calero, M., Rostagno, A., Matsubara, E., Zlokovic, B., Frangione, B., and Ghiso, J. (2000). Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc Res Tech 550, 305-315.
19. Castaño, E. M., Prelli, F., Pras, M., and Frangione, B. (1995). Apolipoprotein E carboxyl-terminal fragments are complexed to amyloids A and L. Implications for amyloidogenesis and Alzheimer's disease. J Biol Chem 270, 17610-17615.
20. Cedazo-Mínguez, A., and Cowburn, R. F. (2001). AApolipoprotein E: a major piece in the Alzheimer's disease puzzle. J Cell Mol Med 5, 254-266.
21. Chauhan, V., Wang, X., Ramsamy, T., Milne, R. W., and Sparks, D. L. (1998). Evidence for lipid-dependent structural changes in specific domains of apolipoprotein B100. Biochemistry 37, 3735-3742.
22. Chisolm, G. M., and Steinberg, D. (2000). The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 28, 1815-1826.
23. Chiti, F., Webster, P., Taddei, N., Clark, A., Stefani, M., Ramponi, G., and Dobson, C. M. (1999). Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci U S A 96, 3590-3594.
24. Cho, H. S., Hyman, B. T., Greenberg, S. M., and Rebeck, G. W. (2001). Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation. J Neuropathol Exp Neurol 60, 342-349.
25. Clark, J. I., and Muchowski, P. J. (2000). Small heat-shock proteins and their potential role in human disease. Curr Opin Struct Biol 10, 52-59.
26. Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., and Pericak-Vance, M. A. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
27. Damaschun, G., Damaschun, H., Fabian, H., Gast, K., Kröber, R., Wieske, M., and Zirwer, D. (2000). Conversion of yeast phosphoglycerate kinase into amyloid-like structure. Proteins 39, 204-211.
28. de Sousa, M. M., Vital, C., Ostler, D., Fernandes, R., Pouget-Abadie, J., Carles, D., and Saraiva, M. J. (2000). Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. Am J Pathol 156, 1911-1917.
29. Derham, B. K., and Harding, J. J. (1999). Alpha-crystallin as a molecular chaperone. Prog Retin Eye Res 18, 463-509.
30. Dobson, C. M. (2002). Getting out of shape. Nature 418, 729-730.
31. Dobson, C. M. (2003). Protein folding and misfolding. Nature 426, 884-890.
32. Eriksson, M., Schönland, S., Yumlu, S., Hegenbart, U., von Hutten, H., Gioeva, Z., Lohse, P., Büttner, J., Schmidt, H., and Röcken, C. (2009). Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. J Mol Diagn 11, 257-262.
33. Evans, K. C., Berger, E. P., Cho, C. G., Weisgraber, K. H., and Lansbury, P. T. Jr. (1995). Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci U S A 92, 763-767.
34. Fändrich, M., Fletcher, M. A., and Dobson, C. M. (2001). Amyloid fibrils from muscle myoglobin. Nature 410, 165-166.
35. Frangione, B., Castaño, E. M., Wisniewski, T., Ghiso, J., Prelli, F., and Vidal, R. (1996). Apolipoprotein E and amyloidogenesis. Ciba Found Symp 199, 132-141, discussion 141-145.
36. Garner, B., Waldeck, A. R., Witting, P. K., Rye, K. A., and Stocker, R. (1998). Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 273, 6088-6095.
37. Genschel, J., Haas, R., Pröpsting, M. J., and Schmidt, H. H. (1998). Apolipoprotein A-I induced amyloidosis. FEBS Lett 430, 145-149.
38. Griffin, M. D., Mok, M. L., Wilson, L. M., Pham, C. L., Waddington, L. J., Perugini, M. A., and Howlett, G. J. (2008). Phospholipid interaction induces molecular-level polymorphism in apolipoprotein C-II amyloid fibrils via alternative assembly pathways. J Mol Biol 375, 240-256.
39. Gunzburg, M. J., Perugini, M. A., and Howlett, G. J. (2007). Structural basis for the recognition and cross-linking of amyloid fibrils by human apolipoprotein E. J Biol Chem 282, 35831-35841.
40. Häggqvist, B., Näslund, J., Sletten, K., Westermark, G. T., Mucchiano, G., Tjernberg, L. O., Nordstedt, C., Engström, U., and Westermark, P. (1999). Medin: an integral fragment of aortic smooth muscle cellproduced lactadherin forms the most common human amyloid. Proc Natl Acad Sci U S A 96, 8669-8674.
41. Hatters, D. M., and Howlett, G. J. (2002). The structural basis for amyloid formation by plasma apolipoproteins: a review. Eur Biophys J 31, 2-8.
42. Hatters, D. M., Lawrence, L. J., and Howlett, G. J. (2001a). Submicellar phospholipid accelerates amyloid formation by apolipoprotein C-II. FEBS Lett 494, 220-224.
43. Hatters, D. M., Lindner, R. A., Carver, J. A., and Howlett, G. J. (2001b). The molecular chaperone, alpha-crystallin, inhibits amyloid formation by apolipoprotein C-II. J Biol Chem 276, 33755-33761.
44. Hatters, D. M., MacPhee, C. E., Lawrence, L. J., Sawyer, W. H., and Howlett, G. J. (2000). Human apolipoprotein C-II forms twisted amyloid ribbons and closed loops. Biochemistry 39, 8276-8283.
45. Hatters, D. M., MacRaild, C. A., Daniels, R., Gosal, W. S., Thomson, N. H., Jones, J. A., Davis, J. J., MacPhee, C. E., Dobson, C. M., and Howlett, G. J. (2003). The circularization of amyloid fibrils formed by apolipoprotein C-II. Biophys J 85, 3979-3990.
46. Hatters, D. M., Wilson, M. R., Easterbrook-Smith, S. B., and Howlett, G. J. (2002). Suppression of apolipoprotein C-II amyloid formation by the extracellular chaperone, clusterin. Eur J Biochem 269, 2789-2794.
47. Hatters, D. M., Zhong, N., Rutenber, E., and Weisgraber, K. H. (2006). Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils. J Mol Biol 361, 932-944.
48. Havel, R. J., Fielding, C. J., Olivecrona, T., Shore, V. G., Fielding, P. E., and Egelrud, T. (1973). Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoproteins lipase from different sources. Biochemistry 12, 1828-1833.
49. Higgins, G. A., Large, C. H., Rupniak, H. T., and Barnes, J. C. (1997). Apolipoprotein E and Alzheimer's disease: a review of recent studies. Pharmacol Biochem Behav 56, 675-685.
50. Higuchi, K., Kitagawa, K., Naiki, H., Hanada, K., Hosokawa, M., and Takeda, T. (1991a). Polymorphism of apolipoprotein A-II (apoA-II) among inbred strains of mice. Relationship between the molecular type of apoA-II and mouse senile amyloidosis. Biochem J 279, 427-433.
51. Higuchi, K., Naiki, H., Kitagawa, K., Hosokawa, M., and Takeda, T. (1991b). Mouse senile amyloidosis. ASSAM amyloidosis in mice presents universally as a systemic age-associated amyloidosis. Virchows Arch B Cell Pathol Incl Mol Pathol 60, 231-238.
52. Howlett, G. J., and Moore, K. J. (2006). Untangling the role of amyloid in atherosclerosis. Curr Opin Lipidol 17, 541-547.
53. Humphreys, D. T., Carver, J. A., Easterbrook-Smith, S. B., and Wilson, M. R. (1999). Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 274, 6875-6881.
54. Hung, A., Griffin, M. D., Howlett, G. J., and Yarovsky, I. (2008). Effects of oxidation, pH and lipids on amyloidogenic peptide structure: implications for fibril formation? Eur Biophys J 38, 99-110.
55. Hung, A., Griffin, M. D., Howlett, G. J., and Yarovsky, I. (2009). Lipids enhance apolipoprotein C-II-derived amyloidogenic peptide oligomerization but inhibit fibril formation. J Phys Chem B 113, 9447-9453.
56. Kawano, M., Kawakami, M., Otsuka, M., Yashima, H., Yaginuma, T., and Ueki, A. (1995). Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease. Clin Chim Acta 2239, 209-211.
57. Kinnunen, P. K., Jackson, R. L., Smith, L. C., Gotto, A. M. Jr, and Sparrow, J. T. (1977). Activation of lipoprotein lipase by native and synthetic fragments of human plasma apolipoprotein C-II. Proc Natl Acad Sci U S A 74, 4848-4851.
58. Kisilevsky, R. (2000). The relation of proteoglycans, serum amyloid P and apo E to amyloidosis current status, 2000. Amyloid 7, 23-25.
59. Knight, J. D., and Miranker, A. D. (2004). Phospholipid catalysis of diabetic amyloid assembly. J Mol Biol 341, 1175-1187.
60. Koistinaho, M., Lin, S., Wu, X., Esterman, M., Koger, D., Hanson, J., Higgs, R., Liu, F., Malkani, S., Bales, K. R., et al. (2004). Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 10, 719-726.
61. Kuriyama, M., Takahashi, K., Yamano, T., Hokezu, Y., Togo, S., Osame, M., and Igakura, T. (1994). Low levels of serum apolipoprotein A I and A II in senile dementia. Jpn J Psychiatry Neurol 48, 589-593.
62. Lange, U., Boss, B., Teichmann, J., Klör, H. U., and Neeck, G. (2000). Serum amyloid A-an indicator of inflammation in ankylosing spondylitis. Rheumatol Int 19, 119-122.
63. LaRosa, J. C., Levy, R. I., Herbert, P., Lux, S. E., and Fredrickson, D. S. (1970). A specific apoprotein activator for lipoprotein lipase. Biochem Biophys Res Commun 41, 57-62.
64. Legge, F. S., Binger, K. J., Griffin, M. D., Howlett, G. J., Scanlon, D., Treutlein, H., and Yarovsky, I. (2009). Effect of oxidation and mutation on the conformational dynamics and fibril assembly of amyloidogenic peptides derived from apolipoprotein C-II. J Phys Chem B 113, 14006-14014.
65. Legge, F. S., Treutlein, H., Howlett, G. J., and Yarovsky, I. (2007). Molecular dynamics simulations of a fibrillogenic peptide derived from apolipoprotein C-II. Biophys Chem 130, 102-113.
66. Li, Q., Min, J., Ahn, Y. H., Namm, J., Kim, E. M., Lui, R., Kim, H. Y., Ji, Y., Wu, H., Wisniewski, T., et al. (2007). Styryl-based compounds as potential in vivo imaging agents for beta-amyloid plaques. Chembiochem 8, 1679-1687.
67. MacRaild, C. A., Hatters, D. M., Howlett, G. J., and Gooley, P. R. (2001). NMR structure of human apolipoprotein C-II in the presence of sodium dodecyl sulfate. Biochemistry 40, 5414-5421.
68. MacRaild, C. A., Hatters, D. M., Lawrence, L. J., and Howlett, G. J. (2003). Sedimentation velocity analysis of flexible macromolecules: self-association and tangling of amyloid fibrils. Biophys J 84, 2562-2569.
69. MacRaild, C. A., Howlett, G. J., and Gooley, P. R. (2004a). The structure and interactions of human apolipoprotein C-II in dodecyl phosphocholine. Biochemistry 43, 8084-8093.
70. MacRaild, C. A., Stewart, C. R., Mok, Y. F., Gunzburg, M. J., Perugini, M. A., Lawrence, L. J., Tirtaatmadja, V., Cooper-White, J. J., and Howlett, G. J. (2004b). Non-fibrillar components of amyloid deposits mediate the self-association and tangling of amyloid fibrils. J Biol Chem 279, 21038-21045.
71. Mak, P. A., Laffitte, B. A., Desrumaux, C., Joseph, S. B., Curtiss, L. K., Mangelsdorf, D. J., Tontonoz, P., and Edwards, P. A. (2002). Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J Biol Chem 277, 31900-31908.
72. May, P. C., and Finch, C. E. (1992). Sulfated glycoprotein 2: new relationships of this multifunctional protein to neurodegeneration. Trends Neurosci 15, 391-396.
73. Medeiros, L. A., Khan, T., El Khoury, J. B., Pham, C. L., Hatters, D. M., Howlett, G. J., Lopez, R., O'Brien, K. D., and Moore, K. J. (2004). Fibrillar amyloid protein present in atheroma activates CD36 signal transduction. J Biol Chem 279, 10643-10648.
74. Merched, A., Xia, Y., Visvikis, S., Serot, J. M., and Siest, G. (2000). Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging 21, 27-30.
75. Mok, Y.F., Ryan, T.M., Yang, S., Hatters, D.M., Howlett, G.J., and Griffin, M.D. (2010).Sedimentation velocity analysis of amyloid oligomers and fibrils using fluorescence detection. Methods. doi:10.1016/j.ymeth.2010.10.004
76. Moore, K. J., El Khoury, J., Medeiros, L. A., Terada, K., Geula, C., Luster, A. D., and Freeman, M. W. (2002). A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J Biol Chem 277, 47373-47379.
77. Mucchiano, G., Cornwell, G. G. 3rd, and Westermark, P. (1992). Senile aortic amyloid. Evidence for two distinct forms of localized deposits. Am J Pathol 140, 871-877.
78. Mucchiano, G. I., Häggqvist, B., Sletten, K., and Westermark, P. (2001a). Apolipoprotein A-1-derived amyloid in atherosclerotic plaques of the human aorta. J Pathol 193, 270-275.
79. Mucchiano, G. I., Jonasson, L., Häggqvist, B., Einarsson, E., and Westermark, P. (2001b). Apolipoprotein A-I-derived amyloid in atherosclerosis. Its association with plasma levels of apolipoprotein A-I and cholesterol. Am J Clin Pathol 115, 298-303.
80. Myers, S. L., Jones, S., Jahn, T. R., Morten, I. J., Tennent, G. A., Hewitt, E. W., and Radford, S. E. (2006). A systematic study of the effect of physiological factors on beta2-microglobulin amyloid formation at neutral pH. Biochemistry 45, 2311-2321.
81. Naiki, H., Gejyo, F., and Nakakuki, K. (1997). Concentrationdependent inhibitory effects of apolipoprotein E on Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry 36, 6243-6250.
82. Naiki, H., Hasegawa, K., Yamaguchi, I., Nakamura, H., Gejyo, F., and Nakakuki, K. (1998). Apolipoprotein E and antioxidants have different mechanisms of inhibiting Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry 37, 17882-17889.
83. Näslund, J., Thyberg, J., Tjernberg, L. O., Wernstedt, C., Karlström, A. R., Bogdanovic, N., Gandy, S. E., Lannfelt, L., Terenius, L., and Nordstedt, C. (1995). Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain. Neuron 15, 219-228.
84. O'Brien, K. D., Olin, K. L., Alpers, C. E., Chiu, W., Ferguson, M., Hudkins, K., Wight, T. N., and Chait, A. (1998). Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation 98, 519-527.
85. Obici, L., Franceschini, G., Calabresi, L., Giorgetti, S., Stoppini, M., Merlini, G., and Bellotti, V. (2006). Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid 13, 191-205.
86. Ozawa, D., Yagi, H., Ban, T., Kameda, A., Kawakami, T., Naiki, H., and Goto, Y. (2009). Destruction of amyloid fibrils of a beta2-microglobulin fragment by laser beam irradiation. J Biol Chem 284, 1009-1017.
87. Pepys, M. B. (2006). Amyloidosis. Annu Rev Med 57, 223-241.
88. Pepys, M. B., Booth, D. R., Huchinson, W. L., Gallimore, J. R., Collins, P. M., and Hohenester, E. (1997). Amyloid P component. A critical review. AMYLOID 4, 274-295.
89. Pepys, M. B., Herbert, J., Hutchinson, W. L., Tennent, G. A., Lachmann, H. J., Gallimore, J. R., Lovat, L. B., Bartfai, T., Alanine, A., Hertel, C., et al. (2002). Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417, 254-259.
90. Permanne, B., Perez, C., Soto, C., Frangione, B., and Wisniewski, T. (1997). Detection of apolipoprotein E/dimeric soluble amyloid beta complexes in Alzheimer's disease brain supernatants. Biochem Biophys Res Commun 240, 715-720.
91. Pham, C. L., Hatters, D. M., Lawrence, L. J., and Howlett, G. J. (2002). Cross-linking and amyloid formation by N- and C-terminal cysteine derivatives of human apolipoprotein C-II. Biochemistry 41, 14313-14322.
92. Puchtler, H., and Sweat, F. (1962). Amidoblack as a stain for hemoglobin. Arch Pathol 73, 245-249.
93. Röcken, C., Tautenhahn, J., Bühling, F., Sachwitz, D., Vöckler, S., Goette, A., and Bürger, T. (2006). Prevalence and pathology of amyloid in atherosclerotic arteries. Arterioscler Thromb Vasc Biol 26, 676-677.
94. Ross, R. (1999). Atherosclerosis-an inflammatory disease. N Engl J Med 340, 115-126.
95. Ryan, T. M., Griffin, M. D., Teoh, C. L., Ooi, J., and Howlett, G. J. (2011). High-Affinity Amphipathic Modulators of Amyloid Fibril Nucleation and Elongation. J Mol Biol 406, 416-429.
96. Ryan, T. M., Howlett, G. J., and Bailey, M. F. (2008). Fluorescence detection of a lipid-induced tetrameric intermediate in amyloid fibril formation by apolipoprotein C-II. J Biol Chem 283, 35118-35128.
97. Ryan, T. M., Teoh, C. L., Griffin, M. D., Bailey, M. F., Schuck, P., and Howlett, G. J. (2010). Phospholipids enhance nucleation but not elongation of apolipoprotein C-II amyloid fibrils. J Mol Biol 399, 731-740.
98. Saczynski, J. S., White, L., Peila, R. L., Rodriguez, B. L., and Launer, L. J. (2007). The relation between apolipoprotein A-I and dementia: the Honolulu-Asia aging study. Am J Epidemiol 165, 985-992.
99. Saunders, A. M., Strittmatter, W. J., Schmechel, D., George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993). Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 443, 1467-1472.
100. Segrest, J. P., Garber, D. W., Brouillette, C. G., Harvey, S. C., and Anantharamaiah, G. M. (1994). The amphipathic alpha helix: a multifunctional structural motif in plasma apolipoproteins. Adv Protein Chem 45, 303-369.
101. Sipe, J. D., and Cohen, A. S. (2000). Review: history of the amyloid fibril. J Struct Biol 130, 88-98.
102. Soto, C., Castaño, E. M., Prelli, F., Kumar, R. A., and Baumann, M. (1995). Apolipoprotein E increases the fibrillogenic potential of synthetic peptides derived from Alzheimer's, gelsolin and AA amyloids. FEBS Lett 371, 110-114.
103. Stadtman, E. R., and Levine, R. L. (2000). Protein oxidation. Ann N Y Acad Sci 899, 191-208.
104. Stewart, C. R., Wilson, L. M., Zhang, Q., Pham, C. L., Waddington, L. J., Staples, M. K., Stapleton, D., Kelly, J. W., and Howlett, G. J. (2007). Oxidized cholesterol metabolites found in human atherosclerotic lesions promote apolipoprotein C-II amyloid fibril formation. Biochemistry 46, 5552-5561.
105. Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., and Roses, A. D. (1993). Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A 90, 8098-8102.
106. Tennent, G. A., Lovat, L. B., and Pepys, M. B. (1995). Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A 92, 4299-4303.
107. Teoh, C. L., Pham, C. L., Todorova, N., Hung, A., Lincoln, C. N., Lees, E., Lam, Y. H., Binger, K. J., Thomson, N. H., Radford, S. E., et al. (2011a). A structural model for apolipoprotein C-II amyloid fibrils: experimental characterization and molecular dynamics simulations. J Mol Biol 405, 1246-1266.
108. Teoh, C. L., Yagi, H., Griffin, M. D., Goto, Y., and Howlett, G. J. (2011b). Visualization of polymorphism in apolipoprotein C-II amyloid fibrils. J Biochem 149, 67-74.
109. Todorova, N., Hung, A., Maaser, S. M., Griffin, M. D., Karas, J., Howlett, G. J., and Yarovsky, I. (2010). Effects of mutation on the amyloidogenic propensity of apolipoprotein C-II(60-70) peptide. Phys Chem Chem Phys 12, 14762-14774.
110. Westermark, G. T., Johnson, K. H., and Westermark, P. (1999). Staining methods for identification of amyloid in tissue. Methods Enzymol 309, 3-25.
111. Westermark, P., Mucchiano, G., Marthin, T., Johnson, K. H., and Sletten, K. (1995). Apolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques. Am J Pathol 147, 1186-1192.
112. Wilson, L. M., Mok, Y. F., Binger, K. J., Griffin, M. D., Mertens, H. D., Lin, F., Wade, J. D., Gooley, P. R., and Howlett, G. J. (2007). A structural core within apolipoprotein C-II amyloid fibrils identified using hydrogen exchange and proteolysis. J Mol Biol 366, 1639-1651.
113. Wisniewski, T., Lalowski, M., Golabek, A., Vogel, T., and Frangione, B. (1995). Is Alzheimer's disease an apolipoprotein E amyloidosis? Lancet 345, 956-958.
114. Wong, Y. Q., Binger, K. J., Howlett, G. J., and Griffin, M. D. (2010). Methionine oxidation induces amyloid fibril formation by full-length apolipoprotein A-I. Proc Natl Acad Sci U S A 107, 1977-1982.
115. Yagi, H., Ban, T., Morigaki, K., Naiki, H., and Goto, Y. (2007). Visualization and classification of amyloid beta supramolecular assemblies. Biochemistry 46, 15009-15017.
116. Yagi, H., Ozawa, D., Sakurai, K., Kawakami, T., Kuyama, H., Nishimura, O., Shimanouchi, T., Kuboi, R., Naiki, H., and Goto, Y. (2010). Laser-induced propagation and destruction of amyloid beta fibrils. J Biol Chem 285, 19660-19667.
117. Zhang, Q., Powers, E. T., Nieva, J., Huff, M. E., Dendle, M. A., Bieschke, J., Glabe, C. G., Eschenmoser, A., Wentworth, P. Jr, Lerner, R. A., et al. (2004). Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc Natl Acad Sci U S A 1101, 4752-4757.
118. Zhao, H., Tuominen, E. K., and Kinnunen, P. K. (2004). Formation of amyloid fibers triggered by phosphatidylserine-containing membranes. Biochemistry 43, 10302-10307.
119. Zheng, L., Nukuna, B., Brennan, M. L., Sun, M., Goormastic, M., Settle, M., Schmitt, D., Fu, X., Thomson, L., Fox, P. L., et al. (2004). Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114, 529-541.